Back to today’s briefing

Story perspectives

FDA Grants Fast Track for Ovarian Cancer Drug Azenosertib

1/10/2025

33 3

Summary

Story summary

Zentalis Pharmaceuticals celebrates a significant milestone as the FDA grants Fast Track Designation for azenosertib, aimed at Cyclin E1 positive patients battling platinum-resistant ovarian cancer. Mark your calendars for January 29, 2025, when updated clinical data will be unveiled. Excitingly, new research underscores the potential of Cyclin E1/CDK2 activation in guiding personalized treatment approaches.

1 of 1

Story summary

Zentalis Pharmaceuticals celebrates a significant milestone as the FDA grants Fast Track Designation for azenosertib, aimed at Cyclin E1 positive patients battling platinum-resistant ovarian cancer. Mark your calendars for January 29, 2025, when updated clinical data will be unveiled. Excitingly, new research underscores the potential of Cyclin E1/CDK2 activation in guiding personalized treatment approaches.